Gastroenterology
Volume 141, Issue 6 , Pages 1963-1967 , December 2011

Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?

  • Pratima Sharma
    • ,
  • Anna S. Lok

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Anna S. Lok, MD, Alice Lohrman Andrews Research Professor in Hepatology, University of Michigan Health System, 1500 E Medical Center Drive, 3912, Taubman Center, SPC 5362, Ann Arbor, Michigan 48109. fax: (734) 936-7392

References 

  1. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374
  2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  4. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436:933–938
  5. Schlutter J. Therapeutics: new drugs hit the target. Nature 474:S5–S7.
  6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416.
  7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206
  8. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997–1002
  9. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50:1709–1718
  10. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology;53:1742–1751.
  11. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–462
  12. Rong L, Dahari H, Ribeiro RM, et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2:30ra32.
  13. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–1475
  14. Zuezem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141:2047–2055
  15. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in Telaprevir phase 3 clinical trials. J Hepatol. 2011;54:s4
  16. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects. Hepatology. 2010;52(LB-1):400A
  17. Lawitz E, Rodriguez-Torres M, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol. 2011;54:S543
  18. Lok AS, Gardiner DF, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol. 2011;54:s536
  19. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med;364:2417–2428.
  20. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186–189

 Conflict of interest Dr Lok receives research grant support from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Roche, and Merck, and has served on the advisory/Data and Safety Monitoring Panel for Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, and Roche.

 Funding Dr Sharma is supported by National Institutes of Health (NIH) grant KO8 DK-088946.

PII: S0016-5085(11)01463-6

doi: 10.1053/j.gastro.2011.10.020

Gastroenterology
Volume 141, Issue 6 , Pages 1963-1967 , December 2011

Article Tools

* Image Usage & Resolution